Drug decision

• Health & Medicine

New treatment for Waldenstrom’s macroglobulinaemia in England

1 October 2022

• Health & Medicine

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

13 September 2022

• Health & Medicine

New targeted treatment for early breast cancer could reduce risk of relapse

A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning. A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning.

21 July 2022

• Health & Medicine

NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia

Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England

23 May 2022

• Health & Medicine

Triple negative breast cancer drug given initial ‘no’ for NHS in England

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer. Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

8 April 2022

• Health & Medicine

Immunotherapy treatment fast tracked to treat lung cancer patients in England

Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England. Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.

28 January 2022

• Health & Medicine

First targeted treatment approved for advanced prostate cancer on NHS in Scotland

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland. The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

13 October 2021